Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene [Yahoo! Finance]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Yahoo! Finance
-- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolerability Profile -- -- Strengthened Balance Sheet with Gross Proceeds of Approximately $45.0 Million from Recent Equity Financing, Extending Cash Runway into 2Q 2025 -- CAMBRIDGE, Mass., January 08, 2024 BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene. "We are beginning the year with tremendous momentum toward our mission of delivering tamibarotene as a new standard of care for the frontline treatment of hematologic malignancies," said Conley Chee, Chief Executive Officer of Syros Pharmaceuticals. "Last month, we announced encouraging initial data from the randomized portion of the SELECT-AML-1 Phase 2 trial, which demonstrated a 10
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML [Yahoo! Finance]Yahoo! Finance
- Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression [Yahoo! Finance]Yahoo! Finance
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionBusiness Wire
SYRS
Earnings
- 3/27/24 - Miss
SYRS
Analyst Actions
- 4/1/24 - HC Wainwright
SYRS
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- SYRS's page on the SEC website